Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | YTD Return | |
---|---|---|---|
All Industries | 100.00% | 7.37% | |
Drug Manufacturers - General | 34.84% | 15.85% | |
Healthcare Plans | 13.40% | 0.27% | |
Medical Devices | 11.62% | -1.82% | |
Diagnostics & Research | 11.45% | 7.58% | |
Biotechnology | 11.40% | -0.19% | |
Medical Instruments & Supplies | 6.86% | 11.24% | |
Medical Care Facilities | 3.19% | 26.26% | |
Drug Manufacturers - Specialty & Generic | 2.77% | -0.72% | |
Medical Distribution | 2.27% | 8.53% | |
Health Information Services | 2.07% | 9.40% | |
Pharmaceutical Retailers | 0.14% | -58.57% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
891.68 | 929.03 | 11.98% | Buy | ||||
558.76 | 616.08 | 7.70% | Buy | ||||
160.62 | 156.96 | 5.77% | Buy | ||||
189.93 | 179.27 | 5.01% | Buy | ||||
114.55 | 128.55 | 4.33% | Buy | ||||
596.18 | 630.67 | 3.40% | Buy | ||||
268.11 | 260.75 | 2.89% | Buy | ||||
108.71 | 124.37 | 2.82% | Buy | ||||
322.49 | 298.37 | 2.59% | Buy | ||||
463.43 | 477.07 | 2.46% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
149.98 | 40.661B | 0.09% | ||
274.47 | 21.092B | 0.10% | ||
142.17 | 7.976B | 0.45% | ||
95.54 | 7.812B | 0.35% | ||
55.82 | 4.88B | 0.40% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
225.99 | 48.824B | 0.30% | ||
95.30 | 48.824B | 0.30% | ||
137.32 | 21.092B | 0.10% | ||
97.64 | 15.167B | 0.80% | ||
97.33 | 15.167B | 0.80% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Myriad Genetics, Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
RatingPrice TargetAnalyst Report: Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetAnalyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetAnalyst Report: Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target